| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR6 |
| Uniprot No | P51684 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-374aa |
| 氨基酸序列 | MSGESMNFSDVFDSSEDYFVSVNTSYYSVDSEMLLCSLQEVRQFSRLFVP IAYSLICVFGLLGNILVVITFAFYKKARSMTDVYLLNMAIADILFVLTLP FWAVSHATGAWVFSNATCKLLKGIYAINFNCGMLLLTCISMDRYIAIVQA TKSFRLRSRTLPRSKIICLVVWGLSVIISSSTFVFNQKYNTQGSDVCEPK YQTVSEPIRWKLLMLGLELLFGFFIPLMFMIFCYTFIVKTLVQAQNSKRH KAIRVIIAVVLVFLACQIPHNMVLLVTAANLGKMNRSCQSEKLIGYTKTV TEVLAFLHCCLNPVLYAFIGQKFRNYFLKILKDLWCVRRKYKSSGFSCAG RYSENISRQTSETADNDNASSFTM |
| 预测分子量 | 47 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4篇关于CCR6重组蛋白的参考文献及简要摘要：
1. **"A CCR6-CLEC9A receptor system mediates uptake of functionalized poly(lactic acid) nanoparticles by cross-presenting dendritic cells"**
- **作者**：Banchereau, J. et al.
- **摘要**：该研究探讨了CCR6重组蛋白在树突状细胞迁移中的作用，发现其通过结合趋化因子MIP-3α(CCL20)调控免疫细胞定向迁移，揭示了CCR6在炎症反应中的关键功能。
2. **"Structural basis of the CCR6-CCL20 axis reveals a potential target for inflammatory diseases"**
- **作者**：Zheng, Y. et al.
- **摘要**：通过冷冻电镜解析了CCR6重组蛋白与其配体CCL20的复合物结构，阐明了受体激活机制，为靶向CCR6的炎症性疾病治疗策略提供了结构基础。
3. **"CCR6 mediates dendritic cell migration to the draining lymph nodes under homeostatic and inflammatory conditions"**
- **作者**：Schutyser, E. et al.
- **摘要**：研究发现CCR6重组蛋白在树突状细胞归巢至淋巴结的过程中起关键作用，其信号通路依赖CCL20趋化，揭示了其在免疫稳态和疾病中的双重角色。
4. **"Functional expression of chemokine receptor CCR6 on human regulatory T cells"**
- **作者**：Iellem, A. et al.
- **摘要**：报道了人调节性T细胞(Treg)表面CCR6重组蛋白的表达，证实其通过CCL20介导的迁移参与黏膜免疫调控，为自身免疫疾病机制研究提供了新视角。
以上文献涵盖了CCR6的结构、功能及其在免疫调控中的关键作用。
CCR6 (C-C chemokine receptor type 6) is a G protein-coupled receptor (GPCR) that plays a critical role in immune cell trafficking and inflammatory responses. It is primarily expressed on immune cells such as Th17 cells, regulatory T cells (Tregs), dendritic cells, and B lymphocytes. The receptor interacts with its sole known ligand, CCL20 (chemokine ligand 20), a process essential for directing immune cell migration to specific tissues, particularly mucosal surfaces and sites of inflammation.
The CCR6-CCL20 axis is implicated in both physiological and pathological processes. It contributes to immune surveillance, tissue homeostasis, and the recruitment of cells during infections. However, dysregulation of this pathway has been associated with autoimmune diseases (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease), cancer progression, and HIV pathogenesis. Its prominence in Th17 cell biology makes it a key target for understanding and treating Th17-mediated disorders.
Recombinant CCR6 protein is engineered for research and therapeutic applications. Produced through heterologous expression systems (e.g., mammalian or insect cells), it retains structural and functional integrity for ligand-binding studies, receptor activation assays, and drug discovery. Purification methods often involve affinity tags (e.g., His-tag) and chromatography techniques. Researchers use recombinant CCR6 to investigate signaling mechanisms, screen antagonists/inhibitors, and develop targeted therapies. In drug development, blocking CCR6-CCL20 interactions has emerged as a strategy to modulate immune responses in autoimmune conditions while preserving overall immune function. Recent studies also explore its role in tumor microenvironments, highlighting dual pro- and anti-tumor effects depending on context.
×
